Pfizer said on Thursday its hemophilia therapy, Hympavzi, met the main goal of a late-stage study in patients with certain ...

Best-in-class innovations in workplace AI are highlighted by Newsweek 's AI Impact Award winners in the workplace categories: ...

U.S. health officials have expanded warnings about a rare heart side effect associated with the two leading COVID-19 vaccines ...

The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.

Robert F. Kennedy Jr. had fired all 17 members of a key vaccine panel. Now his new panel recommended a new infant RSV vaccine ...

From drug trials to mechanistic insights, EULAR 2025 delivers wide-ranging data that may inform tomorrow’s standards in ...

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third ...

Three Fool.com contributors have identified no-brainer stocks to buy for under $100 right now. Here's why they picked two big ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...